ASCO/EHA/ICML 2021 – Christian Buske
Christian Buske relates to recent developments with respect to the role of BTK inhibitors and their potential future combination partners in the treatment of patients with Waldenström’s macroglobulinemia, the results of the iNNOVATE study and personalized treatment according to genotypes.
Here is the full ASCO/EHA/ICML 2021 report.
More posts
Zanubrutinib in relapsed/refractory marginal zone lymphoma: MAGNOLIA
Zanubrutinib in relapsed/refractory marginal zone lymphoma: MAGNOLIA B-cell rec
Mantle cell lymphoma: improving outcomes in difficult-to-treat patient populations
Mantle cell lymphoma: improving outcomes in difficult-to-treat patient populations
Extending anti-PD-1–based options in the setting of Hodgkin lymphoma
Extending anti-PD-1–based options in the setting of Hodgkin lymphoma Patients w
Successful inhibition of PI3K, BTK, BCL2 and other targets in various B-cell malignancies
Successful inhibition of PI3K, BTK, BCL2 and other targets in various B-cell malign
Waldenström’s macroglobulinemia: outcome optimization via combinations
Waldenström’s macroglobulinemia: outcome optimization via combinations Final an
CLL/SLL: current perspectives across a range of potent agents
CLL/SLL: current perspectives across a range of potent agents ALPINE: zanubruti
